autophagy related 9BGenealiases: APG9L2 · NOS3AS · SONE
Q-omics provides the consensus-scored ATG9B profile across patient tissues and cancer cell-line models. ATG9B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ATG9B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ATG9B RNA expression shows 14,679 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where ATG9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATG9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATG9B survival associations across molecular data types. ATG9B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATG9B RNA expression–survival associations across cancer types. High ATG9B expression shows unfavorable associations in KIRP, LIHC, MESO, LGG and SKCM, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ATG9B RNA expression.
This table summarizes ATG9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ATG9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATG9B shows higher tumor expression in COAD, KIRC, LUAD, BLCA, BRCA and READ. The COAD box plot shows higher ATG9B RNA expression in tumor versus normal tissue (log2 FC = +2.391, t-test p < 0.001).
This table shows molecular features associated with ATG9B in patient tissues and cancer cell lines. In patient samples, ATG9B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATG9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
